Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

The prognostic value of measurable residual disease (MRD) by flow cytometry in acute myeloid leukemia (AML) patients treated with non-intensive therapy is relatively unexplored. The clinical value of MRD threshold below 0.1% is also unknown after non-intensive therapy. In this study, MRD to a sensit...

Full description

Bibliographic Details
Main Authors: Shin Yeu Ong, Melinda Tan Si Yun, Nurul Aidah Abdul Halim, Dheepa Christopher, Wei Ying Jen, Christian Gallardo, Angeline Tan Hwee Yim, Yeow Kheong Woon, Heng Joo Ng, Melissa Ooi, Gee Chuan Wong
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
acute myeloid leukemia
venetoclax
measurable residual disease
Online Access:https://www.mdpi.com/2072-6694/14/15/3576

Internet

https://www.mdpi.com/2072-6694/14/15/3576

Similar Items